[ransomnote]

You ought to see the MSM articles flooding the zone in just the past 3 hours “It’s fine, ignore death, take AstraZeneca.”
~~~~~~~~~~~
I think all those regions were alarmed by patients’ response to that AstraZeneca lab experiment on them so they paused administration, an then our medical facists were alarmed that it would impede planned rollout here. So the US probably heckled the EU to ‘make it right’ and VOILA! All those countries reporting medical problems are ignored and now the bureaucrats are ‘right’.

[StAnDeliver]

"I think all those regions were alarmed by patients’ response to that AstraZeneca lab experiment on them so they paused administration, an then our medical facists were alarmed that it would impede planned rollout here. So the US probably heckled the EU to ‘make it right’ and VOILA! All those countries reporting medical problems are ignored and now the bureaucrats are ‘right’."

You nailed it.

[Cathi]

ransomnote, you wrote, “All those countries reporting medical problems are ignored and now the bureaucrats are ‘right’.”

Yes, it is amazing how naive many people are to how these decisions are actually made...:-) The following is a short part from a “hacked” and confirmed by the EMA as an accurate email which provides information on how these “decisions are really made.”

“At a minimum we can say that the TC was interesting, the atmosphere was rather tense, at times even a bit unpleasant, and provides a hint on what EMA may expect if the expectations are not being met, irrespective if such expectations are realistic or not.

The real added value of today’s TC in my view is that we have more clarity now on what may not be acceptable now to the EC, i.e. a delay of several weeks between the authorization granted by the FDA/MHRA (under whatever form) and a CMA opinion issued by the EMA. The political fallout seems to be too high, even if the “technical” level at the MSs (as it was referred to by the commissioner) could defend such a delay in order to make the outcome of the scientific review as robust as possible.

Although we know the whatever we do (speeding up the process to align as much as possible with the approval timing by the FDA/MHRA versus taking the time needed to have robust assurance in particular as regards CMC and safety will have a very big challenge addressing questions and criticisms from the various parties (EC, MSs at political level, EP, media, the general public) in case of delay of several weeks.”